Statement of Changes in Beneficial Ownership (Form 4)

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person * GORDON CARL L 2. Issuer Name and Ticker or Trading Symbol ADARx Pharmaceuticals, Inc. [ADRX] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) __X__ Director __X__ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) C/O ADARX PHARMACEUTICALS, INC., 5871 OBERLIN DRIVE, SUITE 200 3. Date of Earliest Transaction (Month/Day/Year) 09/28/2026 (Street) SAN DIEGO, CA 92121 4. If Amendment, Date Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 09/28/2026 C 10,690,530 A (1) 10,690,530 I See footnotes(3)(6) Common Stock 09/28/2026 C 2,000,962 A (1) 12,691,492 I See footnotes(3)(6) Common Stock 09/28/2026 C 769,601 A (1) 13,461,093 I See footnotes(3)(6) Common Stock 09/28/2026 C 564,187 A (1) 14,025,280 I See footnotes(3)(6) Common Stock 09/28/2026 P 300,249(2) A $17 14,325,529 I See footnotes(3)(6) Common Stock 09/28/2026 C 7,127,019 A (1) 7,127,019 I See footnotes(4)(6) Common Stock 09/28/2026 C 1,333,975 A (1) 8,460,994 I See footnotes(4)(6) Common Stock 09/28/2026 C 513,067 A (1) 8,974,061 I See footnotes(4)(6) Common Stock 09/28/2026 C 256,448 A (1) 9,230,509 I See footnotes(4)(6) Common Stock 09/28/2026 P 61,516(2) A $17 9,292,025 I See footnotes(4)(6) Common Stock 09/28/2026 P 588,235(2) A $17 588,235 I See footnotes(5)(6)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.		SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series A Preferred Stock	(1)	09/28/2026		C			10,690,530	(1)	(1)	Common Stock	10,690,530	$ 0	0	I	See footnotes(3)(6)
Series B Preferred Stock	(1)	09/28/2026		C			2,000,962	(1)	(1)	Common Stock	2,000,962	$ 0	0	I	See footnotes(3)(6)
Series B-1 Preferred Stock	(1)	09/28/2026		C			769,601	(1)	(1)	Common Stock	769,601	$ 0	0	I	See footnotes(3)(6)
Series C Preferred Stock	(1)	09/28/2026		C			564,187	(1)	(1)	Common Stock	564,187	$ 0	0	I	See footnotes(3)(6)
Series A Preferred Stock	(1)	09/28/2026		C			7,127,019	(1)	(1)	Common Stock	7,127,019	$ 0	0	I	See footnotes(4)(6)
Series B Preferred Stock	(1)	09/28/2026		C			1,333,975	(1)	(1)	Common Stock	1,333,975	$ 0	0	I	See footnotes(4)(6)
Series B-1 Preferred Stock	(1)	09/28/2026		C			513,067	(1)	(1)	Common Stock	513,067	$ 0	0	I	See footnotes(4)(6)
Series C Preferred Stock	(1)	09/28/2026		C			256,448	(1)	(1)	Common Stock	256,448	$ 0	0	I	See footnotes(4)(6)

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
GORDON CARL L C/O ADARX PHARMACEUTICALS, INC. 5871 OBERLIN DRIVE, SUITE 200 SAN DIEGO, CA 92121	X	X

Signatures

/s/ Carl L. Gordon		09/30/2026
**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	Each share of Series A Preferred Stock, Series B Preferred Stock, Series B-1 Preferred Stock, and Series C Preferred Stock (collectively, the "Preferred Stock") automatically converted on a 1-for-1.1717 basis into shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock has no expiration date.
(2)	Reflects shares of the Issuer's Common Stock purchased in the Issuer's initial public offering.
(3)	These securities are held directly by OrbiMed Private Investments VII, LP ("OPI VII"). OrbiMed Capital GP VII LLC ("GP VII") is the general partner of OPI VII. OrbiMed Advisors LLC ("OrbiMed Advisors") is the managing member of GP VII. By virtue of such relationships, GP VII and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OPI VII and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of the Reporting Person, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OPI VII.
(4)	These securities are held directly by OrbiMed Israel Partners II, L.P. ("OIP II"). OrbiMed Israel GP II, L.P. ("Israel GP") is the general partner of OIP II. OrbiMed Advisors Israel II Limited ("Advisors Israel") is the general partner of Israel GP. By virtue of such relationships, Israel GP and Advisors Israel may be deemed to have voting power and investment power over the securities held by OIP II and as a result, may be deemed to have beneficial ownership over such securities. Advisors Israel exercises this investment and voting power through a management committee comprised of the Reporting Person, David P. Bonita, and Erez Chimovits, each of whom disclaims beneficial ownership of the shares held by OIP II.
(5)	These securities are held directly by OrbiMed Genesis Master Fund, L.P. ("OrbiMed Genesis"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of OrbiMed Genesis. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting power and investment power over the securities held by OrbiMed Genesis and as a result, may be deemed to have beneficial ownership over such securities. OrbiMed Advisors exercises voting and investment power through a management committee comprised of the Reporting Person, W. Carter Neild, and Geoffrey C. Hsu, each of whom disclaims beneficial ownership of the shares held by OrbiMed Genesis.
(6)	Each of the Reporting Person, OrbiMed Advisors, GP VII, Israel GP, Advisors Israel, and Genesis GP disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any of such entity or person is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.